Stocks›Healthcare›MXCT

MXCT

MaxCyte, Inc.

NasdaqResearch view

$1.17−1.68%

Sep 25 close · 1D EOD · Databento

HealthcareServices-Commercial Physical & Biological ResearchMicro-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

What’s next

Expected around mid November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 12, 2025 and Nov 6, 2024, after the close.

Last report

Aug 12, 2026+9.45%

after the close

Last 4, next close

median 8.13% either way

up 2 of 4

Every report since 2024 →

DateEventSourceNext close

Aug 12Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗+9.45%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

13 big days: a close more than 8.12% from the one before, three times MXCT’s median day (2.71%). On 1 of 13, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, May 26, 2026

13Aug 19, 2026
Aug 19, 2026Nothing in our recordNo MXCT story, brief or results filing in our record that dayGroup +3.9% did not move with it
+3.9% did not move with itINCY +4.0 · CRL +3.9 · IQV +3.9 · MEDP +3.0
+9.45%
12Aug 13, 2026
Aug 13, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.7% did not move with it
−0.7% did not move with itMEDP −2.5 · CRL −1.1 · INCY −0.2 · IQV −0.1
+9.45%
11Jul 17, 2026
Jul 17, 2026Nothing in our recordNo MXCT story, brief or results filing in our record that dayGroup −1.0% did not move with it
−1.0% did not move with itCRL −2.1 · IQV −2.0 · INCY +0.5 · MEDP −0.0
−8.15%
10May 28, 2026
May 28, 2026Nothing in our recordNo MXCT story, brief or results filing in our record that dayGroup +7.0% moved the same way
+7.0% moved the same wayCRL +10.2 · IQV +9.3 · MEDP +4.7 · INCY +0.2
+8.33%
9May 13, 2026
May 13, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.9% did not move with it
−0.9% did not move with itCRL −3.5 · IQV −1.5 · MEDP +1.0 · INCY −0.3
+24.06%
8Mar 18, 2026
Mar 18, 2026Before our storiesGroup −0.5% did not move with it
−0.5% did not move with itCRL +2.2 · INCY −2.1 · IQV −0.8 · MEDP −0.1
−8.63%
7Mar 5, 2026
Mar 5, 2026Before our storiesGroup +0.6% did not move with it
+0.6% did not move with itINCY −1.6 · CRL +1.0 · MEDP +0.8 · IQV +0.3
+8.89%
6Dec 22, 2025
Dec 22, 2025Before our storiesGroup +1.1% did not move with it
+1.1% did not move with itCRL +3.0 · INCY −1.9 · IQV +1.7 · MEDP +0.6
+8.67%
5Nov 6, 2025
Nov 6, 2025ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.1% did not move with it
−0.1% did not move with itCRL +1.9 · MEDP −1.1 · INCY −0.5 · IQV +0.3
−11.98%
4Oct 20, 2025
Oct 20, 2025Before our storiesGroup +3.1% did not move with it
+3.1% did not move with itIQV +3.7 · CRL +3.1 · MEDP +3.1 · INCY −1.6
+8.70%
3Oct 17, 2025
Oct 17, 2025Before our storiesGroup +0.8% did not move with it
+0.8% did not move with itCRL +2.0 · MEDP +1.3 · IQV −0.6 · INCY +0.3
−9.04%
2Oct 15, 2025
Oct 15, 2025Before our storiesGroup −0.1% did not move with it
−0.1% did not move with itINCY +2.5 · IQV −0.8 · MEDP −0.5 · CRL +0.3
+10.91%
1Oct 8, 2025
Oct 8, 2025Before our storiesGroup −0.1% did not move with it
−0.1% did not move with itINCY −2.0 · CRL +2.0 · MEDP −0.2 · IQV −0.1
+9.68%

A story on the same day is not a cause, and a group move is not proof either. Group: IQV, INCY, MEDP, CRL, the largest companies in MXCT’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$121M

Revenue$33.0M−14.50%

Net income$-44.6M

EPS, diluted$-0.42−7.70%

Gross margin81.2%

Operating margin-157.1%

Return on equity-26.0%

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$120.8M

Enterprise Value$100.7M

Income$-44.6M

Sales$33.0M

Book/sh$1.66

Cash/sh$0.19

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio7.77

Current Ratio8.30

Debt/Eq—

EPS (ttm)$-0.42

EPS this Y-7.7%

EPS past 3/5Y—

Sales past 3/5Y-9.3%

EPS Y/Y TTM-7.7%

Sales Y/Y TTM-14.5%

Shs Outstand103.21M

ROA-22.0%

ROE-26.0%

ROIC-27.1%

Gross Margin81.2%

Oper. Margin-157.1%

Profit Margin-135.1%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$33.9M

FY21

$44.3M

FY22

$41.3M

FY23

$38.6M

FY24

$33.0M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$33.9M	$44.3M	$41.3M	$38.6M	$33.0M
Gross Profit	$30.2M	$39.2M	$36.5M	$31.5M	$26.8M
Operating Income	$-18.2M	$-27.4M	$-48.3M	$-51.2M	$-51.9M
Net Income	$-19.1M	$-23.6M	$-37.9M	$-41.1M	$-44.6M
Diluted EPS	$-0.21	$-0.23	$-0.37	$-0.39	$-0.42
Operating Cash Flow	$-10.7M	$-14.8M	$-21.7M	$-27.6M	$-34.4M
Free Cash Flow	$-14.5M	$-33.3M	$-25.4M	$-29.3M	$-36.2M

Same industry

In the screener →

IQV$44.5B INCY$25.1B MEDP$17.3B CRL$14.0B ICLR$13.2B ABSI$1.7B OABI$670M NRC$433M

Build basket with MXCT Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.